Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moderna, Inc. (NASDAQ: MRNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, proxy statements and other key documents filed with the U.S. Securities and Exchange Commission. For a commercial-stage biotechnology company focused on mRNA medicines, these filings offer detailed insight into its financial condition, governance, pipeline priorities and material agreements.
Investors can review Form 8-K current reports where Moderna describes significant events such as quarterly and semiannual financial results, new credit facilities and major business updates. For example, the company has used Form 8-K to report its entry into a $1.5 billion Credit and Guaranty Agreement, to furnish quarterly earnings press releases and to highlight pipeline and strategy updates presented at its Analyst Day.
The page also includes proxy materials such as the DEF 14A, where Moderna explains proposals submitted to shareholders, outlines compensation and incentive structures, and discusses governance matters. A recent definitive proxy statement describes a one-time stock option exchange program for non-Executive Committee employees, including its rationale, design features and potential impact on shareholders.
Through these filings, users can examine Moderna’s capital structure and liquidity arrangements, including the terms of its credit facility, guarantees by subsidiaries and financial covenants such as minimum liquidity requirements. They can also see how the company communicates its strategic priorities, cost-efficiency plans and cash breakeven targets in official documents.
Stock Titan enhances this information by organizing filings chronologically and by type, and by pairing them with AI-powered summaries that highlight the main points from lengthy documents. This helps readers quickly understand the significance of Moderna’s 8-Ks, proxy statements and other SEC reports without having to parse every page, while still allowing full access to the underlying filings for deeper analysis.
Moderna, Inc. reported that the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research issued a Refusal-to-File letter for the biologics license application for its investigational seasonal influenza vaccine, mRNA-1010, and will not initiate a review. The letter cited Moderna’s use of a licensed standard-dose influenza vaccine comparator rather than what the agency described as the “best-available standard of care,” and did not raise specific safety or efficacy concerns about mRNA-1010. Moderna notes this position differs from prior written FDA feedback on its Phase 3 design, and has requested a Type A meeting to clarify the path forward. The company’s mRNA-1010 applications have been accepted for review in the EU, Canada and Australia, and Moderna states it does not expect an impact on its 2026 financial guidance, while still targeting potential approvals beginning in late 2026 or early 2027 outside the U.S.
Moderna, Inc. reported that the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research issued a Refusal-to-File letter for the biologics license application for its investigational seasonal influenza vaccine, mRNA-1010, and will not initiate a review. The letter cited Moderna’s use of a licensed standard-dose influenza vaccine comparator rather than what the agency described as the “best-available standard of care,” and did not raise specific safety or efficacy concerns about mRNA-1010. Moderna notes this position differs from prior written FDA feedback on its Phase 3 design, and has requested a Type A meeting to clarify the path forward. The company’s mRNA-1010 applications have been accepted for review in the EU, Canada and Australia, and Moderna states it does not expect an impact on its 2026 financial guidance, while still targeting potential approvals beginning in late 2026 or early 2027 outside the U.S.
Baillie Gifford & Co, a Scotland-based investment adviser, reports beneficial ownership of 20,580,514 shares of Moderna, Inc. common stock, representing about 5.27% of the class. It has sole power to vote 20,033,351 shares and sole power to dispose of all 20,580,514 shares.
The shares are held by Baillie Gifford & Co and/or its investment adviser subsidiaries, including Baillie Gifford Overseas Limited, on behalf of investment advisory clients such as funds and institutional accounts. The position is certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Moderna.
FMR LLC and Abigail P. Johnson have filed Amendment No. 1 to a Schedule 13G reporting a significant stake in Moderna Inc. common stock. As of the 01/30/2026 event date, they beneficially own 41,301,468.88 shares, representing 10.6% of Moderna’s outstanding common stock.
FMR LLC reports sole voting power over 41,192,005.42 shares and sole dispositive power over 41,301,468.88 shares. Abigail P. Johnson reports sole dispositive power over 41,301,468.88 shares and no voting power. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Moderna. One or more other persons may receive dividends or sale proceeds from these shares, but no such person has more than 5% of the class.
FMR LLC has filed a Schedule 13G reporting beneficial ownership of 27,961,310.82 shares of Moderna Inc. common stock, representing 7.2% of the class as of the stated event date. All of these shares are reported with sole dispositive power and no shared voting or dispositive power.
Abigail P. Johnson is also listed as a reporting person, with the same 27,961,310.82 shares beneficially owned through sole dispositive power and no voting or shared dispositive power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Moderna.
Moderna, Inc. provided preliminary, unaudited figures for its fiscal year ended December 31, 2025 in connection with a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company expects approximately $1.9 billion in revenue for 2025 and GAAP operating expenses of $5.0–$5.2 billion, indicating that reported operating costs are expected to significantly exceed revenue. Moderna also currently expects to have about $8.1 billion in cash, cash equivalents and investments in marketable securities as of December 31, 2025, highlighting a substantial liquidity position. All figures are preliminary, unaudited, and may change as the 2025 year-end audit is completed.
Moderna, Inc. completed an employee stock option exchange, replacing underwater options with new options at a market-based price. The offer expired at 3:59 p.m. Eastern Time on December 12, 2025, with 2,865 eligible employees participating. The company accepted options covering 4,328,461 shares of common stock, which represented 79.9% of the shares underlying eligible options.
All tendered options were cancelled on December 12, 2025, and Moderna granted replacement options covering 1,668,237 shares under its 2018 Stock Option and Incentive Plan. The new options carry an exercise price of $29.46 per share, equal to the Nasdaq Global Select Market closing price on December 12, 2025. Vesting terms follow the structure described in the company’s previously distributed offer materials.
Moderna director Noubar B. Afeyan, through Flagship Pioneering, Inc., exercised stock options for 23,853 shares of Moderna common stock at $10.90 per share on December 11, 2025, and on the same day sold 23,853 shares at $29.485 per share.
After these transactions, Flagship Pioneering held 3,924 Moderna shares, while affiliated funds held 3,880,328 shares through Flagship Ventures Fund IV, L.P. and 747,897 shares through Flagship Ventures Fund IV-Rx, L.P. Afeyan also directly owned 2,224,015 shares. The options exercised were fully vested, covered 23,853 shares and had been scheduled to expire on February 23, 2026, and Afeyan disclaims beneficial ownership of the fund-held shares except to the extent of his pecuniary interest.
The Chief Executive Officer and director of Moderna, Inc. reported exercising a stock option for 688,073 shares of common stock on 12/11/2025. The option, which was fully vested and scheduled to expire on February 23, 2026, had an exercise price of $10.90 per share. The reporting person paid $7,499,995.70 for the shares and $5,998,279.76 of withholding taxes in cash, for a total of $13,498,275.46, and no shares were sold or withheld to fund the exercise. After the transaction, the reporting person beneficially owned 6,181,970 Moderna shares directly, and additional indirect holdings were reported for Boston Biotech Ventures (9,210,686 shares) and OCHA LLC (6,564,880 shares), for which beneficial ownership is disclaimed except to any pecuniary interest.
Moderna, Inc. reported that a company director sold a small block of shares in an insider transaction. On December 9, 2025, the director sold 504 shares of Moderna common stock at a price of $27.60 per share. The transaction was executed under a Rule 10b5-1 trading plan that was adopted on September 5, 2025, indicating it was pre-arranged. The sale was made to generate cash to cover the tax liability arising from the vesting of restricted stock units. Following this sale, the director beneficially owns 1,515 shares of Moderna common stock directly.
Moderna, Inc. entered into a new Credit and Guaranty Agreement with Ares Capital Corporation and other lenders, providing a $1,500,000,000 term loan facility. At closing, $600,000,000 is funded as an initial term loan, with an additional $900,000,000 available as delayed draw term loans. The first $400,000,000 of delayed draws is available until November 2027, and a further $500,000,000 becomes available until November 2028 if key regulatory milestones tied to the late-stage clinical pipeline are achieved.
Loans bear interest at Term SOFR plus a 5.50% margin or at a base rate plus a 4.50% margin, and mature on November 24, 2030. The facility is guaranteed by specified subsidiaries in the United States, Canada, the United Kingdom, Switzerland and Australia and secured by an all-asset collateral package, subject to customary exceptions. A weekly minimum liquidity covenant requires at least $500,000,000 of cash and cash equivalents, increasing to $750,000,000 if draws exceed $1,000,000,000, with testing suspended when the trailing 30‑day average market capitalization is above $5,000,000,000.